# US 2013/0253053 A1 · Method of Treating Skin with microRNA Modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253053 A1
- Document ID: US20130253053A1
- Status: Published application
- Kind: A1
- Application number: 13/905,708
- Filed: 2013-05-30
- Published: 2013-09-26
- Earliest claimed: 2010-12-28
- Assignees: Avon Products, Inc.
- Applicants: Avon Products, Inc.
- Inventors: Permanan Raaj Khusial; Uma Santhanam; John W. Lyga
- Web page: https://patentgrep.com/patent/US20130253053A1

## CPC

- C07C 311/17: to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- A61K 8/466: {containing sulfonic acid derivatives; Salts}
- A61K 8/4926: {having six membered rings}
- A61K 31/255: of sulfoxy acids or sulfur analogues thereof
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/02: for chemically bleaching or whitening the skin
- A61Q 19/08: Anti-ageing preparations
- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 2800/782: Enzyme inhibitors; Enzyme antagonists
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/148: Screening for cosmetic compounds
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents that suppress or down-regulate microRNA expression in dermal fibroblast, resulting in enhanced production of collagen, elastin and/or fibrillin in the skin. Also provided are methods for screening for activity against specific microRNAs and the methods of using active agents identified by the screening protocol in the treatment of skin.

## Claims

### Claim 1

A method for improving the aesthetic appearance of human skin comprising topically applying to an area of the skin in need thereof an effective amount of an active agent that suppresses miR-29a, having the sequence UAGCACCAUCUGAAAUCGGUUA (SEQ. ID. No.: 1), and/or miR-29b, having the sequence UAGCACCAUUUGAAAUCAGUGUU (SEQ. ID No.: 2), in a cosmetically acceptable vehicle, for a time sufficient to enhance the production of collagen, elastin, and/or fibrillin in the skin,
wherein said active agent is a compound having the structure of formula II:
wherein,
R5, when not hydrogen, is selected from hydrogen; —R or X1; where “m” is an integer from 1 to 4, and, in the case where “m” is 2, 3 or 4, R5 is independently selected at each occurrence; and
R7 and R8 are independently C1-20 hydrocarbon radicals; wherein said C1-20 hydrocarbon radicals may optionally be substituted with a group X1 and/or with from one to six heteroatoms selected from oxygen, nitrogen, and sulfur;
R, R*, and RN are independently hydrogen or a C1-20 hydrocarbon radical; wherein said C1-20 hydrocarbon radical may optionally be substituted with a group X1 and/or with from one to twelve heteroatoms selected from oxygen, nitrogen, and sulfur; and
X1 is selected from the group consisting of —F; —Cl; —Br; —I; —OH; —C≡C—R*; —C≡N; —C(R)═N—RN; —C═N—N(RN)2; —C(═NRN)—N(RN)2; —CH2OH; —CHO; —(C═O)—R*; —CO2H; —CO2−; —CO2R*; —CS2R*; —(C═O)—S—R*; —S—(C═O)—R*; —(C═O)—NH2; —(C═O)—NRNRN; —(C═O)—NHNH2; —O—(C═O)—NHNH2; —(C═S)—NH2; —(C═S)—N(RN)2; —O—(C═O)—H; —O—(C═O)—R*; —O—(C═O)—NH2; —O—(C═O)—NRNRN; —OR*; —SR*; —NH2; —NHRN; —NRN2; —N(RN)3+; —N(RN)—OH; —N(→O)(R*)2; —O—N(RN)2; —N(RN)—O—R*; —N(RN)—N(RN)2; —NRN—(C═O)—R*; —NRNC(═O)O—R*; —NRN—CHO; —NRN—(C═O)—R*; —NRNC(═O)NRN; —N(RN)—C(═O)—N(RN)2; —N(RN)—C(═S)—N(RN)2; —N═C(R*)2; —N═N—RN; —SCN; —NCS; —NSO; —SS—R*; —SO—R*; —SO2—R*; —O—S(═O)2—R*; —S(═O)2—OR*; —N(RN)—SO2—R*; —SO2—N(R*)2; —O—SO3−; —O—S(═O)2—OR*; —O—S(═O)—OR*; —O—S(═O)—R*; —S(═O)—OR*; —S(═O)—R*; —NO; —NO2; —NO3; —O—NO; —O—NO2; —N3; —N2; —N(C2H4); —Si(R*)3; —CF3; —O—CF3; —(C═O)—R*; —P(R*)2; —O—P(═O)(OR*)2; and —P(═O)(OR*)2;
and cosmetically acceptable salts thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said active agent suppresses miR-29a.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said active agent suppresses miR-29b.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said active agent suppresses miR-29a and miR-29b.

### Claim 5 (depends on 1)

The method according to claim 1, wherein R5, when not hydrogen, is alkyl, aryl, arylalkyl, or alkylaryl.

### Claim 6 (depends on 5)

The method according to claim 5, wherein R5 is hydrogen.

### Claim 7 (depends on 1)

The method according to claim 1, wherein RN, R7 and R8 are independently a group R, where R is selected from alkyl, aryl, arylalkyl, and alkylaryl, each being optionally substituted with 1-12 heteroatoms selected from halogen, O, N and S.

### Claim 8 (depends on 1)

The method according to claim 1, wherein R7 is a C1 to C4 alkyl.

### Claim 9 (depends on 5)

The method of claim 5, wherein R7 and R8 independently is a C1 to C4 alkyl or phenyl, and RN is hydrogen or a C1 to C4 alkyl.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the compound (II) has the formula:
or a cosmetically acceptable salt thereof.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said aesthetic improvement of said skin is selected from the group consisting of:
(a) treatment, reduction, and/or prevention of fine lines or wrinkles,
(b) reduction of skin pore size,
(c) improvement in skin thickness, plumpness, and/or tautness;
(d) improvement in skin suppleness and/or softness;
(e) improvement in skin tone, radiance, and/or clarity;
(f) improvement in maintenance and remodeling of elastin;
(g) improvement in skin texture and/or promotion of retexturization;
(h) improvement in skin barrier repair and/or function;
(i) improvement in appearance of skin contours;
(j) restoration of skin luster and/or brightness;
(k) improvement of skin appearance decreased by menopause;
(l) improvement in skin moisturization;
(m) increase in skin elasticity and/or resiliency;
(n) treatment, reduction, and/or prevention of skin sagging; or
(o) reduction of pigment spots.

### Claim 12

A method for identifying active agents useful for improving the aesthetic appearance of skin comprising assaying candidate substances for ability to suppress or down-regulate miR-29a and/or miR-29b in a cell.

### Claim 13 (depends on 11)

The method according to claim 11, wherein said assaying step comprises incubating human dermal fibroblasts with said candidate substance and subsequently measuring the levels of miR-29a and/or miR-29b.

### Claim 14 (depends on 12)

The method according to claim 12, wherein said step of measuring is carried out by qRT-PCR.

### Claim 15

A method of improving the appearance of aging skin by stimulating extracellular matrix proteins selected from the group consisting of collagen, elastin, fibrillin, and combinations thereof comprising topically applying to the skin in need of such stimulation a composition containing an effective amount of an active agent that suppresses miR-29a and/or miR-29b, in a topically acceptable vehicle,
wherein said active agent is a compound having the structure of formula II:
wherein,
R5 is selected from hydrogen; —R; or X1; where “m” is an integer from 0 to 5, and, in the case where “m” is 2, 3 or 4, R5 is independently selected at each occurrence; and
R7 and R8 are independently C1-20 hydrocarbon radicals; wherein said C1-20 hydrocarbon radicals may optionally be substituted with a group X1 and/or with from one to six heteroatoms selected from oxygen, nitrogen, and sulfur;
R, R*, and RN are independently hydrogen or a C1-20 hydrocarbon radical; wherein said C1-20 hydrocarbon radical may optionally be substituted with a group X1 and/or with from one to twelve heteroatoms selected from oxygen, nitrogen, and sulfur; and
X1 is selected from the group consisting of —F; —Cl; —Br; —I; —OH; —C≡C—R*; —C≡N; —C(R)═N—RN; —C═N—N(RN)2; —C(═NRN)—N(RN)2; —CH2OH; —CHO; —(C═O)—R*; —CO2H; —CO2−; —CO2R*; —CS2R*; —(C═O)—S—R*; —S—(C═O)—R*; —(C═O)—NH2; —(C═O)—NRNRN; —(C═O)—NHNH2; —O—(C═O)—NHNH2; —(C═S)—NH2; —(C═S)—N(RN)2; —O—(C═O)—H; —O—(C═O)—R*; —O—(C═O)—NH2; —O—(C═O)—NRNRN; —OR*; —SR*; —NH2; —NHRN; —NRN2; —N(RN)3+; N(RN)—OH; —N(→O)(R*)2; —O—N(RN)2; —N(RN)—O—R*; —N(RN)—N(RN)2; —NRN—(C═O)R*; —NRNC(═O)O—R*; —NRN—CHO; —NRN—(C═O)—R*; —NRNC(═O)NRN; —N(RN)—C(═O)—N(RN)2; —N(RN)—C(═S)—N(RN)2; —N═C(R*)2; —N═N—RN; —SCN; —NCS; —NSO; —SS—R*; —SO—R*; —SO2—R*; —O—S(═O)2—R*; —S(═O)2—OR*; —N(RN)—SO2—R*; —SO2—N(R*)2; —O—SO3−; —O—S(═O)2—OR*; —O—S(═O)—OR*; —O—S(═O)—R*; —S(═O)—OR*; —S(═O)—R*; —NO; —NO2; —NO3; —O—NO; —O—NO2; —N3; —N2; —N(C2H4); —Si(R*)3; —CF3; —O—CF3; —(C═O)—R*; —P(R*)2; —O—P(═O)(OR*)2; and —P(═O)(OR*)2;
and cosmetically acceptable salts thereof.
